Colfax completed the spin-off its fabrication technology and specialty medical technology businesses in a $2.4bn deal.

Colfax, a diversified technology company, completed the spin-off its fabrication technology and specialty medical technology businesses into two differentiated, independent, and publicly-traded companies, in a $2.4bn deal. "This is an exciting day for Colfax and an important step to unlock the full value inherent in our MedTech and FabTech businesses. Now is the right time to build on the momentum in both businesses and enable each to better capitalize on its distinct opportunities. Our abilities to successfully develop talent, drive innovation, leverage our Colfax Business System for continuous improvement and acquire attractive businesses are core to both MedTech and FabTech. We believe a separation will better position each business to execute tailored strategies to deliver above-market growth, margin expansion and strong, consistent free cash flow," Matt Trerotola, Colfax President and CEO.